JUBLPHARMA — Jubilant Pharmova Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Jubilant Pharmova, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	C2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	59,758	60,985	61,302	62,817	67,029
Cost of Revenue
Gross Profit	43,275	43,451	43,432	40,589	45,622
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	48,004	50,011	53,057	61,087	63,529
Operating Profit	11,754	10,974	8,245	1,730	3,500
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10,129	8,711	6,304	278	1,705
Provision for Income Taxes
Net Income After Taxes	6,060	5,739	4,130	-649	727
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	8,982	8,359	4,139	-610	771
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,982	8,359	4,139	-610	771
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	40.4	38.3	26.1	5.6	9.4
Dividends per Share